NASDAQ
Denali Therapeutics Inc. (DNLI) has a free cash flow growth of -33.59% as of Friday, May 29, 2026. This represents a 239.20% decrease compared to its 12-month average of -9.90%. Free cash flow growth tracks the year-over-year percentage change in cash generated after capital expenditures.
No price data available for this timeframe.